{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:02:10Z","timestamp":1783576930462,"version":"3.55.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11625-0","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:23:11Z","timestamp":1775820191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of chemokine receptors in leukemia: implications for prognosis and therapeutic strategies"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1692-3512","authenticated-orcid":false,"given":"Fatemeh","family":"Karimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6501-5959","authenticated-orcid":false,"given":"Mohammad Reza","family":"Moghaddasnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1171-7918","authenticated-orcid":false,"given":"Negar Sadat","family":"Sherafat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-5594","authenticated-orcid":false,"given":"Najmaldin","family":"Saki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"11625_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-immunol-041015-055649","volume":"34","author":"O Schulz","year":"2016","unstructured":"Schulz O, Hammerschmidt SI, Moschovakis GL, F\u00f6rster R (2016) Chemokines and Chemokine Receptors in Lymphoid Tissue Dynamics. Annu Rev Immunol 34:203\u2013242","journal-title":"Annu Rev Immunol"},{"issue":"16","key":"11625_CR2","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1111\/febs.14466","volume":"285","author":"CE Hughes","year":"2018","unstructured":"Hughes CE, Nibbs RJB (2018) A guide to chemokines and their receptors. Febs j 285(16):2944\u20132971","journal-title":"Febs j"},{"issue":"1","key":"11625_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/MOH.0b013e3282f29012","volume":"15","author":"HE Broxmeyer","year":"2008","unstructured":"Broxmeyer HE (2008) Chemokines in hematopoiesis. Curr Opin Hematol 15(1):49\u201358","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"11625_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/path.5924","volume":"258","author":"T Skroblyn","year":"2022","unstructured":"Skroblyn T et al (2022) CXCR4 mediates leukemic cell migration and survival in the testicular microenvironment. J Pathol 258(1):12\u201325","journal-title":"J Pathol"},{"issue":"1","key":"11625_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13045-021-01060-y","volume":"14","author":"Z Hong","year":"2021","unstructured":"Hong Z et al (2021) Targeting chemokines for acute lymphoblastic leukemia therapy. J Hematol Oncol 14(1):48","journal-title":"J Hematol Oncol"},{"issue":"10","key":"11625_CR6","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.31557\/APJCP.2021.22.10.3377","volume":"22","author":"B Yazdani","year":"2021","unstructured":"Yazdani B et al (2021) CXCL1, CXCL10 and CXCL12 Chemokines are Variously Expressed in Acute Myeloid Leukemia Patients Prior and Post Bone Marrow Transplantation. Asian Pac J Cancer Prev 22(10):3377\u20133384","journal-title":"Asian Pac J Cancer Prev"},{"key":"11625_CR7","doi-asserted-by":"publisher","unstructured":"Mollica Poeta V, Massara M, Capucetti A, Bonecchi R (2019) Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy. Front Immunol, 10 https:\/\/doi.org\/10.3389\/fimmu.2019.00379","DOI":"10.3389\/fimmu.2019.00379"},{"issue":"5","key":"11625_CR8","doi-asserted-by":"publisher","first-page":"a016303","DOI":"10.1101\/cshperspect.a016303","volume":"7","author":"CL Sokol","year":"2015","unstructured":"Sokol CL, Luster AD (2015) The chemokine system in innate immunity. Cold Spring Harb Perspect Biol 7(5):a016303","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"11625_CR9","doi-asserted-by":"publisher","first-page":"L3","DOI":"10.1152\/ajplung.00405.2003","volume":"288","author":"P Puneet","year":"2005","unstructured":"Puneet P, Moochhala S, Bhatia M (2005) Chemokines in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 288(1):L3\u201315","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"5","key":"11625_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1165\/rcmb.2011-0392TR","volume":"46","author":"M Bhatia","year":"2012","unstructured":"Bhatia M, Zemans RL, Jeyaseelan S (2012) Role of chemokines in the pathogenesis of acute lung injury. Am J Respir Cell Mol Biol 46(5):566\u2013572","journal-title":"Am J Respir Cell Mol Biol"},{"key":"11625_CR11","doi-asserted-by":"publisher","first-page":"105092","DOI":"10.1016\/j.phrs.2020.105092","volume":"161","author":"C Huynh","year":"2020","unstructured":"Huynh C, Dingemanse J, Meyer Zu Schwabedissen HE, Sidharta PN (2020) Relevance of the CXCR4\/CXCR7-CXCL12 axis and its effect in pathophysiological conditions. Pharmacol Res 161:105092","journal-title":"Pharmacol Res"},{"issue":"1","key":"11625_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/cancers15010167","volume":"15","author":"T Wu","year":"2022","unstructured":"Wu T et al (2022) The Role of CXC Chemokines in Cancer Progression. Cancers (Basel) 15(1):167","journal-title":"Cancers (Basel)"},{"issue":"8","key":"11625_CR13","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/nrc2444","volume":"8","author":"C Murdoch","year":"2008","unstructured":"Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8(8):618\u2013631","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"11625_CR14","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.3390\/ijms23042168","volume":"23","author":"J Korbecki","year":"2022","unstructured":"Korbecki J et al (2022) CXCR2 Receptor: Regulation of Expression, Signal Transduction, and Involvement in Cancer. Int J Mol Sci 23(4):2168","journal-title":"Int J Mol Sci"},{"issue":"3","key":"11625_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3324\/haematol.10148","volume":"92","author":"\u00d8 Bruserud","year":"2007","unstructured":"Bruserud \u00d8 et al (2007) Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 92(3):332\u2013341","journal-title":"Haematologica"},{"key":"11625_CR16","doi-asserted-by":"publisher","first-page":"584766","DOI":"10.3389\/fonc.2020.584766","volume":"10","author":"C Lu","year":"2020","unstructured":"Lu C et al (2020) Risk Stratification in Acute Myeloid Leukemia Using CXCR Gene Signatures: A Bioinformatics Analysis. Front Oncol 10:584766","journal-title":"Front Oncol"},{"issue":"1","key":"11625_CR17","first-page":"50","volume":"36","author":"JM Horacek","year":"2014","unstructured":"Horacek JM et al (2014) Biochip array technology and evaluation of serum levels of multiple cytokines and adhesion molecules in patients with newly diagnosed acute myeloid leukemia. Exp Oncol 36(1):50\u201351","journal-title":"Exp Oncol"},{"key":"11625_CR18","doi-asserted-by":"publisher","first-page":"204062072095858","DOI":"10.1177\/2040620720958586","volume":"11","author":"W Tang","year":"2020","unstructured":"Tang W, Li Z, Li X, Huo Z (2020) High CXCR2 expression predicts poor prognosis in adult patients with acute myeloid leukemia. Ther Adv Hematol 11:2040620720958586","journal-title":"Ther Adv Hematol"},{"key":"11625_CR19","doi-asserted-by":"publisher","first-page":"e17862","DOI":"10.7717\/peerj.17862","volume":"12","author":"Y Hou","year":"2024","unstructured":"Hou Y et al (2024) Prognostic role of chemokine-related genes in acute myeloid leukemia. PeerJ 12:e17862","journal-title":"PeerJ"},{"issue":"5","key":"11625_CR20","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1111\/ijlh.13512","volume":"43","author":"L Li","year":"2021","unstructured":"Li L, Zhao L, Man J, Liu B (2021) CXCL2 benefits acute myeloid leukemia cells in hypoxia. Int J Lab Hematol 43(5):1085\u20131092","journal-title":"Int J Lab Hematol"},{"issue":"18","key":"11625_CR21","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.3390\/cancers15184555","volume":"15","author":"J Korbecki","year":"2023","unstructured":"Korbecki J et al (2023) The Role of CXCR1, CXCR2, CXCR3, CXCR5, and CXCR6 Ligands in Molecular Cancer Processes and Clinical Aspects of Acute Myeloid Leukemia (AML). Cancers (Basel) 15(18):4555","journal-title":"Cancers (Basel)"},{"issue":"3","key":"11625_CR22","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.bbrc.2018.03.181","volume":"499","author":"Y Li","year":"2018","unstructured":"Li Y et al (2018) CXCL8 is associated with the recurrence of patients with acute myeloid leukemia and cell proliferation in leukemia cell lines. Biochem Biophys Res Commun 499(3):524\u2013530","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"11625_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/08820139.2019.1661429","volume":"49","author":"M Merle","year":"2020","unstructured":"Merle M et al (2020) Serum Chemokine-release Profiles in AML-patients Might Contribute to Predict the Clinical Course of the Disease. Immunol Invest 49(4):365\u2013385","journal-title":"Immunol Invest"},{"issue":"10","key":"11625_CR24","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1182\/blood.V87.10.4382.bloodjournal87104382","volume":"87","author":"P di Francia","year":"1996","unstructured":"di Francia P et al (1996) Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood 87(10):4382\u20134389","journal-title":"Blood"},{"issue":"1","key":"11625_CR25","doi-asserted-by":"publisher","first-page":"15714","DOI":"10.1038\/s41598-017-15953-x","volume":"7","author":"D Risnik","year":"2017","unstructured":"Risnik D et al (2017) Revisiting the role of interleukin-8 in chronic lymphocytic leukemia. Sci Rep 7(1):15714","journal-title":"Sci Rep"},{"key":"11625_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R et al (2018) CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev 63:40\u201347","journal-title":"Cancer Treat Rev"},{"key":"11625_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","volume":"25","author":"DS Chandrashekar","year":"2022","unstructured":"Chandrashekar DS et al (2022) UALCAN: An update to the integrated cancer data analysis platform. Neoplasia 25:18\u201327","journal-title":"Neoplasia"},{"issue":"2","key":"11625_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/bloodadvances.2019001124","volume":"4","author":"H \u00c7elik","year":"2020","unstructured":"\u00c7elik H et al (2020) Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia. Blood Adv 4(2):367\u2013379","journal-title":"Blood Adv"},{"issue":"7","key":"11625_CR29","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s00262-005-0080-z","volume":"55","author":"AM Olsnes","year":"2006","unstructured":"Olsnes AM et al (2006) T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunol Immunother 55(7):830\u2013840","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"11625_CR30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/08820139.2019.1661429","volume":"49","author":"M Merle","year":"2020","unstructured":"Merle M et al (2020) Serum Chemokine-release Profiles in AML-patients Might Contribute to Predict the Clinical Course of the Disease. Immunol Investig 49(4):365\u2013385","journal-title":"Immunol Investig"},{"issue":"1","key":"11625_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/blood-2011-06-357442","volume":"119","author":"Y Lee","year":"2012","unstructured":"Lee Y et al (2012) Protumoral role of monocytes in human B-cell precursor acute lymphoblastic leukemia: involvement of the chemokine CXCL10. Blood 119(1):227\u2013237","journal-title":"Blood"},{"issue":"5","key":"11625_CR32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ajh.23407","volume":"88","author":"C Mart\u00ednez-Laperche","year":"2013","unstructured":"Mart\u00ednez-Laperche C et al (2013) Detection of occult cerebrospinal fluid involvement during maintenance therapy identifies a group of children with acute lymphoblastic leukemia at high risk for relapse. Am J Hematol 88(5):359\u2013364","journal-title":"Am J Hematol"},{"issue":"3","key":"11625_CR33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bcmd.2015.07.001","volume":"55","author":"AM G\u00f3mez","year":"2015","unstructured":"G\u00f3mez AM et al (2015) Chemokines and relapses in childhood acute lymphoblastic leukemia: A role in migration and in resistance to antileukemic drugs. Blood Cells Mol Dis 55(3):220\u2013227","journal-title":"Blood Cells Mol Dis"},{"issue":"20","key":"11625_CR34","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1182\/blood-2013-05-499970","volume":"123","author":"MT Williams","year":"2014","unstructured":"Williams MT et al (2014) Interleukin-15 enhances cellular proliferation and upregulates CNS homing molecules in pre-B acute lymphoblastic leukemia. Blood 123(20):3116\u20133127","journal-title":"Blood"},{"issue":"3","key":"11625_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3324\/haematol.10649","volume":"92","author":"E Oca\u00f1a","year":"2007","unstructured":"Oca\u00f1a E et al (2007) The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells. Haematologica 92(3):349\u2013356","journal-title":"Haematologica"},{"issue":"4","key":"11625_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bcmd.2012.12.003","volume":"50","author":"AA Filip","year":"2013","unstructured":"Filip AA et al (2013) Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages? Blood Cells Mol Dis 50(4):263\u2013270","journal-title":"Blood Cells Mol Dis"},{"issue":"8","key":"11625_CR37","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1007\/s12094-023-03126-4","volume":"25","author":"M Pan","year":"2023","unstructured":"Pan M et al (2023) Targeting CXCL9\/10\/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity. Clin Transl Oncol 25(8):2306\u20132320","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"11625_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1006\/jaut.2002.0613","volume":"19","author":"AR Glabinski","year":"2002","unstructured":"Glabinski AR et al (2002) Experimental autoimmune encephalomyelitis: CC chemokine receptor expression by trafficking cells. J Autoimmun 19(4):175\u2013181","journal-title":"J Autoimmun"},{"issue":"1","key":"11625_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12920-023-01690-w","volume":"17","author":"X Liao","year":"2024","unstructured":"Liao X et al (2024) CC chemokine receptors are prognostic indicators of gastric cancer and are associated with immune infiltration. BMC Med Genomics 17(1):1","journal-title":"BMC Med Genomics"},{"issue":"11","key":"11625_CR40","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2174\/1381612043452640","volume":"10","author":"J Juarez","year":"2004","unstructured":"Juarez J, Bendall L, Bradstock K (2004) Chemokines and their receptors as therapeutic targets: the role of the SDF-1\/CXCR4 axis. Curr Pharm Des 10(11):1245\u20131259","journal-title":"Curr Pharm Des"},{"key":"11625_CR41","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3389\/fonc.2020.01672","volume":"10","author":"D Cancilla","year":"2020","unstructured":"Cancilla D, Rettig MP, DiPersio JF (2020) Targeting CXCR4 in AML and ALL. Front Oncol 10:1672","journal-title":"Front Oncol"},{"issue":"2","key":"11625_CR42","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1182\/blood-2004-02-0566","volume":"104","author":"EJ Rombouts","year":"2004","unstructured":"Rombouts EJ, Pavic B, L\u00f6wenberg B, Ploemacher RE (2004) Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 104(2):550\u2013557","journal-title":"Blood"},{"key":"11625_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cyto.2018.02.020","volume":"109","author":"A Peled","year":"2018","unstructured":"Peled A et al (2018) Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. Cytokine 109:11\u201316","journal-title":"Cytokine"},{"issue":"2","key":"11625_CR44","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11899-015-0255-4","volume":"10","author":"A Rashidi","year":"2015","unstructured":"Rashidi A, Uy GL (2015) Targeting the microenvironment in acute myeloid leukemia. Curr Hematol Malig Rep 10(2):126\u2013131","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"11625_CR45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.semcancer.2003.10.003","volume":"14","author":"F Balkwill","year":"2004","unstructured":"Balkwill F (2004) The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14(3):171\u2013179","journal-title":"Semin Cancer Biol"},{"issue":"31","key":"11625_CR46","doi-asserted-by":"publisher","first-page":"30902","DOI":"10.18632\/oncotarget.5094","volume":"6","author":"EA Sison","year":"2015","unstructured":"Sison EA et al (2015) POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL. Oncotarget 6(31):30902\u201330918","journal-title":"Oncotarget"},{"issue":"6","key":"11625_CR47","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ccell.2015.05.002","volume":"27","author":"LA Pitt","year":"2015","unstructured":"Pitt LA et al (2015) CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance. Cancer Cell 27(6):755\u2013768","journal-title":"Cancer Cell"},{"issue":"4","key":"11625_CR48","doi-asserted-by":"publisher","first-page":"100158","DOI":"10.1016\/j.bneo.2025.100158","volume":"2","author":"B Zd\u00e1rsky","year":"2025","unstructured":"Zd\u00e1rsky B et al (2025) Loss of STAT3 in acute myeloid leukemia favors tissue infiltration linked to CXCR4 signaling. Blood Neoplasia 2(4):100158","journal-title":"Blood Neoplasia"},{"key":"11625_CR49","doi-asserted-by":"crossref","unstructured":"Singh DD, Yadav DK, Shin D (2025) Targeting the CXCR4\/CXCL12 axis to overcome drug resistance in triple-negative breast cancer. Cells, 14(18)","DOI":"10.3390\/cells14181482"},{"issue":"3","key":"11625_CR50","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.pharmthera.2014.07.003","volume":"144","author":"E ten Hacken","year":"2014","unstructured":"ten Hacken E, Burger JA (2014) Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. Pharmacol Ther 144(3):338\u2013348","journal-title":"Pharmacol Ther"},{"issue":"2","key":"11625_CR51","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41435-024-00258-7","volume":"25","author":"X Xue","year":"2024","unstructured":"Xue X et al (2024) CXCR4 overexpression in chronic lymphocytic leukemia associates with poorer prognosis: A prospective, single-center, observational study. Genes Immun 25(2):117\u2013123","journal-title":"Genes Immun"},{"issue":"11","key":"11625_CR52","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1038\/leu.2017.82","volume":"31","author":"M Abraham","year":"2017","unstructured":"Abraham M et al (2017) The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a\/16\u2009\u2013\u20091 expression. Leukemia 31(11):2336\u20132346","journal-title":"Leukemia"},{"issue":"10","key":"11625_CR53","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1038\/s41375-021-01376-1","volume":"35","author":"R Lewis","year":"2021","unstructured":"Lewis R et al (2021) CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness. Leukemia 35(10):2895\u20132905","journal-title":"Leukemia"},{"issue":"9","key":"11625_CR54","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s00262-013-1452-4","volume":"62","author":"B Charbonneau","year":"2013","unstructured":"Charbonneau B et al (2013) CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunol Immunother 62(9):1475\u20131484","journal-title":"Cancer Immunol Immunother"},{"key":"11625_CR55","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3389\/fendo.2019.00471","volume":"10","author":"MG Kazanietz","year":"2019","unstructured":"Kazanietz MG, Durando M, Cooke M (2019) CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond. Front Endocrinol (Lausanne) 10:471","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"11625_CR56","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3324\/haematol.10148","volume":"92","author":"B \u00d8ystein","year":"2007","unstructured":"\u00d8ystein B et al (2007) Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 92(3):332\u2013341","journal-title":"Haematologica"},{"key":"11625_CR57","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","volume":"24","author":"JA Burger","year":"2014","unstructured":"Burger JA, Gribben JG (2014) The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol 24:71\u201381","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"11625_CR58","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1158\/2159-8290.CD-14-0096","volume":"4","author":"K Heinig","year":"2014","unstructured":"Heinig K et al (2014) Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation. Cancer Discov 4(12):1448\u20131465","journal-title":"Cancer Discov"},{"issue":"6793","key":"11625_CR59","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/35018581","volume":"406","author":"KM Ansel","year":"2000","unstructured":"Ansel KM et al (2000) A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406(6793):309\u2013314","journal-title":"Nature"},{"issue":"9","key":"11625_CR60","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1182\/blood-2007-05-089409","volume":"110","author":"A B\u00fcrkle","year":"2007","unstructured":"B\u00fcrkle A et al (2007) Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 110(9):3316\u20133325","journal-title":"Blood"},{"issue":"50","key":"11625_CR61","doi-asserted-by":"publisher","first-page":"7081","DOI":"10.1038\/sj.onc.1210519","volume":"26","author":"M Ticchioni","year":"2007","unstructured":"Ticchioni M et al (2007) Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene 26(50):7081\u20137091","journal-title":"Oncogene"},{"issue":"4","key":"11625_CR62","first-page":"280","volume":"1","author":"C Hu","year":"2004","unstructured":"Hu C et al (2004) PEG10 activation by co-stimulation of CXCR5 and CCR7 essentially contributes to resistance to apoptosis in CD19\u2009+\u2009CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia. Cell Mol Immunol 1(4):280\u2013294","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"11625_CR63","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s41375-020-01063-7","volume":"35","author":"M Sivina","year":"2021","unstructured":"Sivina M et al (2021) CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia 35(6):1610\u20131620","journal-title":"Leukemia"},{"issue":"1","key":"11625_CR64","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4103\/ijh.ijh_9_24","volume":"13","author":"OM Shareef","year":"2024","unstructured":"Shareef OM, Hameed BM (2024) Assessment of CXCL13 plasma level in chronic lymphocytic leukemia and its relation to other prognostic markers. Iraqi J Hematol 13(1):106\u2013109","journal-title":"Iraqi J Hematol"},{"issue":"3","key":"11625_CR65","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1034\/j.1600-0609.2000.90112.x","volume":"64","author":"M Majka","year":"2000","unstructured":"Majka M, Ratajczak J, Kowalska MA, Ratajczak MZ (2000) Binding of stromal derived factor-1alpha (SDF-1alpha) to CXCR4 chemokine receptor in normal human megakaryoblasts but not in platelets induces phosphorylation of mitogen-activated protein kinase p42\/44 (MAPK), ELK-1 transcription factor and serine\/threonine kinase AKT. Eur J Haematol 64(3):164\u2013172","journal-title":"Eur J Haematol"},{"issue":"5","key":"11625_CR66","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/bjh.15670","volume":"185","author":"LS Hiemcke-Jiwa","year":"2019","unstructured":"Hiemcke-Jiwa LS et al (2019) CXCR4 mutations in lymphoplasmacytic lymphoma lead to altered CXCR4 expression. Br J Haematol 185(5):966\u2013969","journal-title":"Br J Haematol"},{"issue":"1","key":"11625_CR67","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/bjh.14807","volume":"179","author":"JM Waldschmidt","year":"2017","unstructured":"Waldschmidt JM et al (2017) CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma. Br J Haematol 179(1):36\u201349","journal-title":"Br J Haematol"},{"issue":"11","key":"11625_CR68","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/17460441.2016.1233176","volume":"11","author":"F Barbieri","year":"2016","unstructured":"Barbieri F et al (2016) Drug design strategies focusing on the CXCR4\/CXCR7\/CXCL12 pathway in leukemia and lymphoma. Expert Opin Drug Discov 11(11):1093\u20131109","journal-title":"Expert Opin Drug Discov"},{"key":"11625_CR69","doi-asserted-by":"publisher","first-page":"174831","DOI":"10.1016\/j.ejphar.2022.174831","volume":"920","author":"M Mehrpouri","year":"2022","unstructured":"Mehrpouri M (2022) The contributory roles of the CXCL12\/CXCR4\/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies. Eur J Pharmacol 920:174831","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"11625_CR70","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1038\/s41598-021-84695-8","volume":"11","author":"XY Cui","year":"2021","unstructured":"Cui XY et al (2021) Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia. Sci Rep 11(1):5127","journal-title":"Sci Rep"},{"issue":"4","key":"11625_CR71","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1006\/jaut.2002.0613","volume":"19","author":"AR Glabinski","year":"2002","unstructured":"Glabinski AR et al (2002) Experimental Autoimmune Encephalomyelitis: CC Chemokine Receptor Expression by Trafficking Cells. J Autoimmun 19(4):175\u2013181","journal-title":"J Autoimmun"},{"key":"11625_CR72","doi-asserted-by":"crossref","unstructured":"Chemokine\/chemokine receptor nomenclature. Cytokine, (2003) 21(1): p. 48\u201349","DOI":"10.1016\/S1043-4666(02)00493-3"},{"issue":"1","key":"11625_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12920-023-01690-w","volume":"17","author":"X Liao","year":"2024","unstructured":"Liao X et al (2024) CC chemokine receptors are prognostic indicators of gastric cancer and are associated with immune infiltration. BMC Med Genom 17(1):1","journal-title":"BMC Med Genom"},{"key":"11625_CR74","doi-asserted-by":"crossref","unstructured":"Zeissig MN et al. (2021) Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo Haematologica. 106(12): 3176\u20133187","DOI":"10.3324\/haematol.2020.253526"},{"issue":"15","key":"11625_CR75","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.4155\/fmc.11.144","volume":"3","author":"AR Karash","year":"2011","unstructured":"Karash AR, Gilchrist A (2011) Therapeutic potential of CCR1 antagonists for multiple myeloma. Future Med Chem 3(15):1889\u20131908","journal-title":"Future Med Chem"},{"key":"11625_CR76","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2023-184464","volume":"142","author":"S Chen","year":"2023","unstructured":"Chen S, Boardman AP, James SE, van den Brink MRM (2023) CCR1-Targeting CAR T Cells for Acute Myeloid Leukemia. Blood 142:4808","journal-title":"Blood"},{"issue":"3","key":"11625_CR77","first-page":"496","volume":"15","author":"Q Gong","year":"2007","unstructured":"Gong Q et al (2007) Effect of CCL23\/myeloid progenitor inhibitory factor 1 (MPIF-1) on the proliferation, apoptosis and differentiation of U937 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 15(3):496\u2013500","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"11625_CR78","doi-asserted-by":"crossref","unstructured":"Ren X et al S128: AML conditioning of the bone marrow microenvironment through ccr1 ligand up-regulation promotes aml stem cell propagation and is mimicked by ageing. LID - e8112156. (2572\u20139241 (Electronic)).","DOI":"10.1097\/01.HS9.0000967424.81121.56"},{"issue":"7","key":"11625_CR79","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.3390\/jcm9072312","volume":"9","author":"I Kholodnyuk","year":"2020","unstructured":"Kholodnyuk I et al (2020) Chemokine Receptors CCR1 and CCR2 on Peripheral Blood Mononuclear Cells of Newly Diagnosed Patients with the CD38-Positive Chronic Lymphocytic Leukemia. J Clin Med 9(7):2312","journal-title":"J Clin Med"},{"issue":"55","key":"11625_CR80","doi-asserted-by":"publisher","first-page":"94591","DOI":"10.18632\/oncotarget.21813","volume":"8","author":"SY Shin","year":"2017","unstructured":"Shin SY et al (2017) C-C motif chemokine receptor 1 (CCR1) is a target of the EGF-AKT-mTOR-STAT3 signaling axis in breast cancer cells. Oncotarget 8(55):94591\u201394605","journal-title":"Oncotarget"},{"issue":"26","key":"11625_CR81","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1038\/onc.2016.515","volume":"36","author":"MHA van Attekum","year":"2017","unstructured":"van Attekum MHA et al (2017) Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia. Oncogene 36(26):3651\u20133660","journal-title":"Oncogene"},{"issue":"4","key":"11625_CR82","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/14728222.2021.1902505","volume":"25","author":"H Hemmatazad","year":"2021","unstructured":"Hemmatazad H, Berger MD (2021) CCR5 is a potential therapeutic target for cancer. Expert Opin Ther Targets 25(4):311\u2013327","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"11625_CR83","first-page":"869","volume":"7","author":"J Zi","year":"2017","unstructured":"Zi J et al (2017) Treatment with the C-C chemokine receptor type 5 (CCR5)-inhibitor maraviroc suppresses growth and induces apoptosis of acute lymphoblastic leukemia cells. Am J Cancer Res 7(4):869\u2013880","journal-title":"Am J Cancer Res"},{"key":"11625_CR84","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cytogfr.2018.08.004","volume":"43","author":"S Binder","year":"2018","unstructured":"Binder S, Luciano M, Horejs-Hoeck J (2018) The cytokine network in acute myeloid leukemia (AML): A focus on pro- and anti-inflammatory mediators. Cytokine Growth Factor Rev 43:8\u201315","journal-title":"Cytokine Growth Factor Rev"},{"key":"11625_CR85","doi-asserted-by":"publisher","first-page":"117071","DOI":"10.1016\/j.lfs.2019.117071","volume":"240","author":"Z Yazdani","year":"2020","unstructured":"Yazdani Z et al (2020) Differential regulatory effects of chemotherapeutic protocol on CCL3_CCL4_CCL5\/CCR5 axes in acute myeloid leukemia patients with monocytic lineage. Life Sci 240:117071","journal-title":"Life Sci"},{"issue":"4","key":"11625_CR86","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/1878-0261.12640","volume":"14","author":"S Waldeck","year":"2020","unstructured":"Waldeck S et al (2020) CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML. Mol Oncol 14(4):779\u2013794","journal-title":"Mol Oncol"},{"issue":"2","key":"11625_CR87","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/pbc.22500","volume":"55","author":"CM Faaij","year":"2010","unstructured":"Faaij CM et al (2010) Chemokine\/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: differential roles for CCR2, CCR5, CXCR4 and CXCR7. Pediatr Blood Cancer 55(2):344\u2013348","journal-title":"Pediatr Blood Cancer"},{"key":"11625_CR88","doi-asserted-by":"publisher","first-page":"p5530650","DOI":"10.1155\/2021\/5530650","volume":"2021","author":"F Magalh\u00e3es-Gama","year":"2021","unstructured":"Magalh\u00e3es-Gama F et al (2021) Imbalance of Chemokines and Cytokines in the Bone Marrow Microenvironment of Children with B-Cell Acute Lymphoblastic Leukemia. J Oncol 2021:p5530650","journal-title":"J Oncol"},{"key":"11625_CR89","doi-asserted-by":"publisher","first-page":"109530","DOI":"10.1016\/j.biopha.2019.109530","volume":"120","author":"G Zhang","year":"2019","unstructured":"Zhang G et al (2019) Investigation of candidate molecular biomarkers for expression profile analysis of the Gene expression omnibus (GEO) in acute lymphocytic leukemia (ALL). Biomed Pharmacother 120:109530","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"11625_CR90","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.cytogfr.2013.03.001","volume":"24","author":"I Comerford","year":"2013","unstructured":"Comerford I et al (2013) A myriad of functions and complex regulation of the CCR7\/CCL19\/CCL21 chemokine axis in the adaptive immune system. Cytokine Growth Factor Rev 24(3):269\u2013283","journal-title":"Cytokine Growth Factor Rev"},{"key":"11625_CR91","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.biocel.2014.07.002","volume":"54","author":"DF Legler","year":"2014","unstructured":"Legler DF, Uetz-von Allmen E, Hauser MA (2014) CCR7: roles in cancer cell dissemination, migration and metastasis formation. Int J Biochem Cell Biol 54:78\u201382","journal-title":"Int J Biochem Cell Biol"},{"issue":"7249","key":"11625_CR92","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/nature08020","volume":"459","author":"S Buonamici","year":"2009","unstructured":"Buonamici S et al (2009) CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 459(7249):1000\u20131004","journal-title":"Nature"},{"issue":"12Supplement","key":"11625_CR93","doi-asserted-by":"publisher","first-page":"LB015","DOI":"10.1158\/1538-7445.AM2022-LB015","volume":"82","author":"A Torres","year":"2022","unstructured":"Torres A et al (2022) Abstract LB015: CCR7-expressing T-cell acute lymphoblastic leukemia mouse model provides a platform for developing novel anti-CCR7 therapies to prevent CNS invasion. Cancer Res 82(12Supplement):LB015\u2013LB015","journal-title":"Cancer Res"},{"issue":"5","key":"11625_CR94","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nri2297","volume":"8","author":"R F\u00f6rster","year":"2008","unstructured":"F\u00f6rster R, Davalos-Misslitz AC, Rot A (2008) CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 8(5):362\u2013371","journal-title":"Nat Rev Immunol"},{"key":"11625_CR95","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1756-8722-6-89","volume":"6","author":"B Somovilla-Crespo","year":"2013","unstructured":"Somovilla-Crespo B et al (2013) Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma. J Hematol Oncol 6:89","journal-title":"J Hematol Oncol"},{"issue":"4","key":"11625_CR96","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.leukres.2005.07.009","volume":"30","author":"A Corcione","year":"2006","unstructured":"Corcione A et al (2006) Chemokine receptor expression and function in childhood acute lymphoblastic leukemia of B-lineage. Leuk Res 30(4):365\u2013372","journal-title":"Leuk Res"},{"issue":"8","key":"11625_CR97","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/00365510600931098","volume":"66","author":"W Luczy\u0144ski","year":"2006","unstructured":"Luczy\u0144ski W et al (2006) Acute lymphoblastic leukaemia cells express CCR7 but not higher amounts of IL-10 after CD40 ligation. Scand J Clin Lab Invest 66(8):695\u2013703","journal-title":"Scand J Clin Lab Invest"},{"issue":"2","key":"11625_CR98","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3324\/haematol.2016.147744","volume":"102","author":"A Alsadeq","year":"2017","unstructured":"Alsadeq A et al (2017) The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system. Haematologica 102(2):346\u2013355","journal-title":"Haematologica"},{"issue":"10","key":"11625_CR99","doi-asserted-by":"publisher","first-page":"6713","DOI":"10.4049\/jimmunol.177.10.6713","volume":"177","author":"H Chunsong","year":"2006","unstructured":"Chunsong H et al (2006) CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23\u2009+\u2009CD5+ B cells. J Immunol 177(10):6713\u20136722","journal-title":"J Immunol"},{"issue":"3","key":"11625_CR100","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/sj.leu.2403626","volume":"19","author":"M Jongen-Lavrencic","year":"2005","unstructured":"Jongen-Lavrencic M, Salesse S, Delwel R, Verfaillie CM (2005) BCR\/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR\/ABL-positive cells. Leukemia 19(3):373\u2013380","journal-title":"Leukemia"},{"issue":"4","key":"11625_CR101","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.bbrc.2015.06.020","volume":"463","author":"K Kubo","year":"2015","unstructured":"Kubo K et al (2015) CCR7 is involved in BCR-ABL\/STAP-2-mediated cell growth in hematopoietic Ba\/F3 cells. Biochem Biophys Res Commun 463(4):825\u2013831","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"11625_CR102","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00262-015-1670-z","volume":"64","author":"C Cuesta-Mateos","year":"2015","unstructured":"Cuesta-Mateos C et al (2015) Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia. Cancer Immunol Immunother 64(6):665\u2013676","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"11625_CR103","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1096\/fj.201701452RR","volume":"32","author":"JM Laufer","year":"2018","unstructured":"Laufer JM, Lyck R, Legler DF (2018) ZAP70 expression enhances chemokine-driven chronic lymphocytic leukemia cell migration and arrest by valency regulation of integrins. Faseb j 32(9):4824\u20134835","journal-title":"Faseb j"},{"issue":"1","key":"11625_CR104","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1182\/asheducation-2018.1.242","volume":"2018","author":"N Jain","year":"2018","unstructured":"Jain N (2018) Selecting Frontline Therapy for CLL in 2018. Hematol Am Soc Hematol Educ Program 2018(1):242\u2013247","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"11625_CR105","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00262-021-03014-2","volume":"71","author":"T Mateu-Albero","year":"2022","unstructured":"Mateu-Albero T et al (2022) Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody. Cancer Immunol Immunother 71(3):627\u2013636","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"11625_CR106","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.4049\/jimmunol.162.10.5671","volume":"162","author":"A Zaballos","year":"1999","unstructured":"Zaballos A et al (1999) Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol 162(10):5671\u20135675","journal-title":"J Immunol"},{"issue":"1","key":"11625_CR107","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-016-0236-7","volume":"9","author":"Z Tu","year":"2016","unstructured":"Tu Z et al (2016) CCR9 in cancer: oncogenic role and therapeutic targeting. J Hematol Oncol 9(1):10","journal-title":"J Hematol Oncol"},{"issue":"1","key":"11625_CR108","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.leukres.2010.07.039","volume":"35","author":"L Zhang","year":"2011","unstructured":"Zhang L et al (2011) Role of Rho-ROCK signaling in MOLT4 cells metastasis induced by CCL25. Leuk Res 35(1):103\u2013109","journal-title":"Leuk Res"},{"issue":"24","key":"11625_CR109","doi-asserted-by":"publisher","first-page":"39033","DOI":"10.18632\/oncotarget.16559","volume":"8","author":"X Deng","year":"2017","unstructured":"Deng X et al (2017) Wnt5a and CCL25 promote adult T-cell acute lymphoblastic leukemia cell migration, invasion and metastasis. Oncotarget 8(24):39033\u201339047","journal-title":"Oncotarget"},{"issue":"5","key":"11625_CR110","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/path.3015","volume":"226","author":"L Mirandola","year":"2012","unstructured":"Mirandola L et al (2012) Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol 226(5):713\u2013722","journal-title":"J Pathol"},{"key":"11625_CR111","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.molimm.2021.10.016","volume":"140","author":"J Li","year":"2021","unstructured":"Li J et al (2021) LINC00853 restrains T cell acute lymphoblastic leukemia invasion and infiltration by regulating CCR9\/CCL25. Mol Immunol 140:267\u2013275","journal-title":"Mol Immunol"},{"key":"11625_CR112","doi-asserted-by":"publisher","unstructured":"Korbecki J et al (2023) The Role of CXCR1, CXCR2, CXCR3, CXCR5, and CXCR6 ligands in molecular cancer processes and clinical aspects of Acute Myeloid Leukemia (AML). Cancers 15. https:\/\/doi.org\/10.3390\/cancers15184555","DOI":"10.3390\/cancers15184555"},{"key":"11625_CR113","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3389\/fimmu.2019.00379","volume":"10","author":"V Mollica Poeta","year":"2019","unstructured":"Mollica Poeta V, Massara M, Capucetti A, Bonecchi R (2019) Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy. Front Immunol 10:379","journal-title":"Front Immunol"},{"key":"11625_CR114","doi-asserted-by":"crossref","unstructured":"Cooper TM et al (2017) A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators\u2019 Consortium study (POE 10\u2009\u2013\u200903). Pediatr Blood Cancer, 64(8)","DOI":"10.1002\/pbc.26414"},{"key":"11625_CR115","doi-asserted-by":"publisher","first-page":"204062072311743","DOI":"10.1177\/20406207231174304","volume":"14","author":"ZD Crees","year":"2023","unstructured":"Crees ZD, Rettig MP, DiPersio JF (2023) Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. Ther Adv Hematol 14:20406207231174304","journal-title":"Ther Adv Hematol"},{"key":"11625_CR116","doi-asserted-by":"crossref","unstructured":"Drouillard D et al (2025) CXCL12 chemokine dimer signaling modulates acute myelogenous leukemia cell migration through altered receptor internalization. bioRxiv","DOI":"10.1101\/2024.08.26.609725"},{"issue":"3","key":"11625_CR117","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.18632\/oncotarget.6465","volume":"7","author":"MK Kashyap","year":"2016","unstructured":"Kashyap MK et al (2016) Ulocuplumab (BMS-936564 \/ MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget 7(3):2809\u20132822","journal-title":"Oncotarget"},{"issue":"2","key":"11625_CR118","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1124\/mol.117.108522","volume":"92","author":"JS Smith","year":"2017","unstructured":"Smith JS et al (2017) C-X-C Motif Chemokine Receptor 3 Splice Variants Differentially Activate Beta-Arrestins to Regulate Downstream Signaling Pathways. Mol Pharmacol 92(2):136\u2013150","journal-title":"Mol Pharmacol"},{"key":"11625_CR119","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fimmu.2018.00077","volume":"9","author":"B Somovilla-Crespo","year":"2018","unstructured":"Somovilla-Crespo B et al (2018) 92R Monoclonal Antibody Inhibits Human CCR9(+) Leukemia Cells Growth in NSG Mice Xenografts. Front Immunol 9:77","journal-title":"Front Immunol"},{"issue":"6152","key":"11625_CR120","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.1241475","volume":"341","author":"Q Tan","year":"2013","unstructured":"Tan Q et al (2013) Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341(6152):1387\u20131390","journal-title":"Science"},{"key":"11625_CR121","doi-asserted-by":"publisher","first-page":"1184014","DOI":"10.3389\/fimmu.2023.1184014","volume":"14","author":"P Grudzien","year":"2023","unstructured":"Grudzien P, Neufeld H, Eyenga ME, Gaponenko V (2023) Development of tolerance to chemokine receptor antagonists: current paradigms and the need for further investigation. Front Immunol 14:1184014","journal-title":"Front Immunol"},{"issue":"11","key":"11625_CR122","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3324\/haematol.2014.113852","volume":"100","author":"DS Krause","year":"2015","unstructured":"Krause DS, Scadden DT (2015) A hostel for the hostile: the bone marrow niche in hematologic neoplasms. Haematologica 100(11):1376\u20131387","journal-title":"Haematologica"},{"issue":"7","key":"11625_CR123","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1128\/AAC.00013-07","volume":"51","author":"ND Stone","year":"2007","unstructured":"Stone ND et al (2007) Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother 51(7):2351\u20132358","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"11625_CR124","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/17425255.2020.1711884","volume":"16","author":"M Miao","year":"2020","unstructured":"Miao M, De Clercq E, Li G (2020) Clinical significance of chemokine receptor antagonists. Expert Opin Drug Metab Toxicol 16(1):11\u201330","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"11625_CR125","doi-asserted-by":"publisher","first-page":"1717666","DOI":"10.3389\/fimmu.2025.1717666","volume":"16","author":"VLS Oliveira","year":"2025","unstructured":"Oliveira VLS, Proost P, Struyf S (2025) Chemokines in the resolution of inflammation: key players and targets for therapeutic modulation. Front Immunol 16:1717666","journal-title":"Front Immunol"},{"key":"11625_CR126","doi-asserted-by":"crossref","unstructured":"Gu S et al (2024) Ligand-Dependent Mechanisms of CC Chemokine Receptor 5 (CCR5) Trafficking Revealed by APEX2 Proximity Labeling Proteomics. bioRxiv","DOI":"10.1101\/2023.11.01.565224"},{"issue":"2","key":"11625_CR127","first-page":"493","volume":"111","author":"NS Naji","year":"2026","unstructured":"Naji NS et al (2026) C-C motif chemokine receptor-like 2 promotes the interferon-\u03b3 signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53. Haematologica 111(2):493\u2013507","journal-title":"Haematologica"},{"issue":"1","key":"11625_CR128","doi-asserted-by":"publisher","first-page":"108055","DOI":"10.1016\/j.jbc.2024.108055","volume":"301","author":"F Pfersdorf","year":"2025","unstructured":"Pfersdorf F, Romanazzi L, Rosenkilde MM, Gustavsson M (2025) Regulation of the chemokine receptors CXCR4 and ACKR3 by receptor activity-modifying proteins. J Biol Chem 301(1):108055","journal-title":"J Biol Chem"},{"issue":"9","key":"11625_CR129","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/13543784.2024.2388567","volume":"33","author":"EA Martino","year":"2024","unstructured":"Martino EA et al (2024) Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies. Expert Opin Investig Drugs 33(9):915\u2013924","journal-title":"Expert Opin Investig Drugs"},{"key":"11625_CR130","doi-asserted-by":"publisher","unstructured":"Korbecki J et al (2024) Clinical Aspects and Significance of \u03b2-Chemokines, \u03b3-Chemokines, and \u03b4-Chemokines in Molecular Cancer Processes in Acute Myeloid Leukemia (AML) and Myelodysplastic Neoplasms (MDS). Cancers 16. https:\/\/doi.org\/10.3390\/cancers16193246","DOI":"10.3390\/cancers16193246"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11625-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11625-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11625-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T13:07:52Z","timestamp":1775826472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11625-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11625"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11625-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"607"}}